A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs

• Main Authors: Itzel Condado-Morales (Author), Fabian Dingfelder (Author), Isabel Waibel (Author), Oliver M. Turnbull (Author), Bhargav Patel (Author), Zheng Cao (Author), Jais Rose Bjelke (Author), Susanne Nedergaard Grell (Author), Anja Bennet (Author), Alissa M. Hummer (Author), Matthew I. J. Raybould (Author), Charlotte M. Deane (Author), Thomas Egebjerg (Author), Nikolai Lorenzen (Author), Paolo Arosio (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecules into successful therapeutics can be hampered by...